Biotech Industry · global
Activating mRNA Only When It Recognizes Diseased Cells: SRTD Raises €31.5 Million to Advance Preclinical Development
German startup SRTD aims to use intracellular RNA signals to control therapeutic protein production and reduce exposure in healthy tissues. The new funding will support its cancer, autoimmune disease and fibrosis pipeline, but selectivity and safety still require step-by-step validation.
After mRNA is delivered to an organ, ensuring that its therapeutic instructions are carried out only in the cells that need them remains a challenge for precision RNA therapies. SRTD Biotech, based in Jülich, Germany, has chosen to add a recognition mechanism to the RNA itself: therapeutic protein production is activated only when disease-associated signals are detected inside cells. On November 9, the company announced the completion of a €31.5 million seed financing round to advance this concept into more comprehensive preclinical development.
According to EU-Startups reporting and an announcement from Mérieux Equity Partners, the round was oversubscribed and led by Mérieux, with NRW.BANK and Boehringer Ingelheim Venture Fund as co-leads. Lilly Ventures, HTGF and Anobis Asset also participated. The funding will support therapeutic candidates for cancer, autoimmune diseases and fibrosis, advancing the studies required for investigational new drug (IND) applications.
SRTD calls its core technology “selectively expressed RNA” (seRNA). According to the company’s technology description, this RNA carries a sensing module that can pair with specific RNA markers inside target cells. Only after recognition occurs is the blocking mechanism that suppresses protein translation released. The design aims to keep therapeutic instructions switched off in cells lacking the marker, reducing the likelihood of therapeutic protein production in healthy tissues.
This intracellular switch also needs to work with a delivery system. The company’s fusion lipid nanoparticles (fLNP) carry RNA to target organs, while seRNA then identifies target cells within those organs, creating two layers of selection at the organ and cellular levels. However, this describes the platform’s intended design; experiments with the drug candidates must still establish whether it can balance distribution, potency and safety under actual conditions of use.
The company currently lists four programs covering hepatocellular carcinoma, lung cancer, liver fibrosis and autoimmune diseases, all at the preclinical stage. The platform has a modular design, allowing recognition signals and therapeutic functions to be adjusted separately: the cancer programs aim to eliminate tumor cells, while the liver fibrosis program focuses on altering the function of diseased cells. These applications share a technological framework, but each must demonstrate that its markers are sufficiently reliable and that its therapeutic effects can be controlled.
The financing also comes with an expansion of the management team: Matthias Alder becomes chief executive officer, Heinz Koeppl serves as chief technology officer, and Jens Hennecke becomes chief business officer. According to the announcement, Hennecke will seek research and development collaborations beyond the company’s own pipeline, indicating that SRTD also hopes to expand the platform’s applications through partnerships; the transaction announced here remains an equity financing.
The funding gives SRTD additional resources to validate its technology, but does not yet demonstrate that its therapies are effective or safer in humans. The financing announcement did not provide complete efficacy, toxicology or human data for the drug candidates. The next key questions are whether disease-associated RNA markers can reliably distinguish diseased cells from healthy ones, and whether the RNA switch can activate unexpectedly. Those results will determine whether the concept of precise expression can advance into clinical development.